cyrilzakka/clinical-trials huggingface dataset:
Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients

This pilot study is aimed at assessing the acute effect of several combinations of lipids differing in their fatty acid composition on glucagon-like-peptide (GLP)-2 and GLP-1 secretion in healthy subjects.

In this study, the investigators aim to investigate the effect of various lipid types on GLP-2 and GLP-1 secretion. This will allow to determine the importance of lipids in nutritional solutions. Moreover, this will allow us to assess whether existing clinical formulas can be improved in order to stimulate GLP-2 and accelerate intestinal recovery.

Eligibility Criteria:
Inclusion Criteria:

* BMI : 19 - 24.9 kg.m-2
* Normal fasting glycemia
* Having obtained his informed consent.

Exclusion Criteria:

* Gastro-intestinal disease (ulcer), pancreatic disease, hepatic disease, metabolic diseases / disorders (diabetes, dyslipidemia), renal disease, cardiovascular disease (arterial hypertension), as determined by the medical screening visit and a blood analysis.
* Have had a gastrointestinal surgery (with the exception of appendices resection).
* Malabsorption disorders
* Lactose intolerance
* Significant weight loss during the past three months (more than 5% of initial weight)
* Have a regular consumption of medication
* Regular supplements (vitamins and minerals) intake during the previous month
* Have an alcohol intake: \> 2 units a day
* Smoker (more than 2 cigarettes a day)
* Illicit substances intake, as stated on the medical screening questionnaire
* Allergy to any food or medication
* Anaemia defined by a number of erythrocytes or hemoglobin Hb or hematocrit Ht which are inferior to laboratory normal ranges
* Having given blood in the past three months or willing to give blood in the 3 months following the completion of the study
* Intense physical activity \> 3 hours per week
* Currently participating or having participated in another clinical trial during the past month.
* Volunteer who cannot be expected to comply with the protocol, including consuming rapidly the study products, chronic medication intake
Incidence, Risk Factor, Treatment and Overall Survival of Locoregionally Recurrent Colon Cancer

Data on disease recurrence was collected for all primary colon cancer patients diagnosed in the Netherlands over the first six months of 2015. Three-year cumulative incidence, risk factors, treatment and three-year OS of locoregionally recurrent colon cancer were determined.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed stage I-III primary colon carcinoma;
* Diagnosed between January 1st and June 30th of 2015;
* Surgical resection of primary colon carcinoma.

Exclusion Criteria:

* Appendiceal localization;
* Neuroendocrine tumor morphology;
Microbiota Community of Irritable Bowel Syndrome in Episodes and Remission Phase

Analyze microbiota community of irritable bowel syndrome in episodes phase and remission phase.

The pathophysiology of IBS is incompletely understood, it may involve an altered intestinal microbiota. Since the microflora composition of IBS is various in different studies, The investigators plan to compare the intestinal microbiota of IBS patients in episodes phase and remission phase with healthy controls,trying to find the difference.

Eligibility Criteria:
Inclusion Criteria:

* the presence of Rome III criteria for IBS ;
* Patients scheduled for colonoscopy examination or having negative screening examinations
* Aged between 18 and 65 years old

Exclusion Criteria:

* Antibiotic, probiotic or laxative usage within 4 weeks.
* organic gastrointestinal diseases
* Severe systematic disease: diabetes mellitus, hepatic, renal or cardiac dysfunction, thyroid disease or tumor etc.
* pregnancy or lactation.
* previous major or complicated abdominal surgery.
* severe endometriosis and dementia
Comparison of Oxford UKA and Sigma UKA With RSA.

Comparison of two unicompartmental knee arthroplasties (UKA), to see if Sigma UKA performs equally good as the Oxford UKA. The study focuses on how well the arthroplasty is fixated to the bone and on the difference in wear of the plastic insert. Finally, the functional outcome after surgery is compared between the two arthroplasties.

Hypothesis:

H1: The Sigma UKA has an equal migration pattern compared to the Oxford UKA with a follow up of two years - that is, no significant difference in migration between 1-2 years follow-up.

H2: The Oxford and Sigma UKA's have comparable polyethylene wear with a follow up of 5 years.

H3: The Oxford and Sigma UKA's have comparable patient perceived outcome measures (PROM) and leg extension power (LEP) postoperative.

H4: BMD of the proximal tibia does not influence migration of the tibial component


Eligibility Criteria:
Inclusion Criteria:

* All eligable patients with medial osteoarthritis of the knee.

Exclusion Criteria:

* - Inflammatory arthritis.
* Patients who are not able to participate in the fast-track surgery program.
* Patients with a contralateral knee arthroplasty.
* Patients who are unable to provide informed consent.
* Disseminated malignant disease (cancer) and treatment with radiation or chemotherapy.
* Serious systemic disease (e.g.. hemiparesis and severe parkinsonism)
* On-going case involving work injury of the knee.
* Female patients with a wish of becoming pregnant in the study period.
Optimizing Stress Ulcer Prophylaxis Practices and Reducing Associated Costs in Intensive Care Units: a Nonrandomized Controlled Study

The study is a prospectively designed, nonrandomized controlled study. It was conducted for six months at the EICU and GICU of a training and research hospital between 1 Jun 2023 and 1 December 2023.

The study involved GICU patients as the standard care services observation group (OG). The use of SUP in the GICU was only monitored and noted. In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP SUP guidelines \[1\]. The study duration was six months concurrently in the EICU and the GICU. Before inclusion, written informed consent was obtained from each patient or their parent(s)/legal guardian(s). Subjects with incomplete data were excluded. The inclusion criteria were patients aged ≥18 years and hospitalized for ≥24 hours in the EICU/GICU. Patients with a history of stomach cancer, admission to the ICU because of GI bleeding, subtotal/total gastrectomy, or receiving a proton pump inhibitor for therapeutic purposes were excluded from the study.

Eligibility Criteria:
Inclusion Criteria:

* The inclusion criteria were patients aged ≥18 years and hospitalized for ≥24 hours in the EICU/GICU.

Exclusion Criteria:

* Patients with a history of stomach cancer, admission to the ICU because of GI bleeding, subtotal/total gastrectomy, or receiving a proton pump inhibitor for therapeutic purposes were excluded from the study.
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.


Eligibility Criteria:
Inclusion Criteria:

* Participants who are administered with atezolizumab for the locally approved indications

Exclusion Criteria:

* Participants with a known hypersensitivity to atezolizumab or to any of the excipients
Staining Potential and Caries Arresting Effect of Silver Diamine Fluoride⁄Potassium Iodide and Silver Diamine Fluoride

the main objective of this study is to evaluate staining potential and Caries Arresting Effect of silver diamine fluoride⁄potassium Iodide and silver diamine fluoride in carious anterior primary teeth

Despite increased attention on caries prevention, not all children receive preventive treatments and large numbers still experience tooth decay. Primary care providers have had little option other than invasive and costly specialist treatment in the hospital under general anesthesia. In this context, there is interest in simple treatments to halt progress of carious lesions after tooth decay onset. Among these simple treatments is silver diamine fluoride (SDF) treatment. The major drawback to SDF treatment has been its black staining, which has limited its use. To counter the staining, researchers have tested SDF treatment immediately followed with application of saturated solution of potassium iodide (KI).

Eligibility Criteria:
Inclusion Criteria:

* Children with carious primary anterior teeth.
* Children with no spontaneous pain

Exclusion Criteria:

* Tooth mobility
* Signs of pulpal or periapical infection
* Severe medical conditions that would not allow management in the clinic
* Sensitivity to silver or other heavy-metal ions
* Presence of any gingival or perioral ulceration or stomatitis
The Effect of Methylphenidate on Motor Learning in Stroke Patients

The purpose of the study is to determine whether methylphenidate facilitates so called short-term plasticity as measures with transcranial magnetic stimulation, in patients with stroke.

Stroke patients are to be examined with transcranial magnetic stimulation (TMS) before and after a short training session. TMS will be used to demonstrate changes in cortical excitability (motor threshold) and intracortical inhibition and facilitation. The effect of methylphenidate on baseline TMS measures will be evaluated as well as the effect on training induced changes in TMS measures (by comparing baseline and posttraining measures). The patients will be trained on two separate occasions, to compare the effect of Methylphenidate to placebo.

Eligibility Criteria:
Inclusion Criteria:

* Less than two months after first stroke.
* Moderate to light hand paralysis
* Measurable MEP in the abductor pollicis brevis muscle
* Able to read and understand the written information
* Signed informed consent

Exclusion Criteria:

* Epilepsy
* Glaucoma
* Hyperthyroidism
* Cardiac arrythmia
* Known heart disease or angina.
* Metal implants
* Pacemaker
* Pregnancy
* Diastolic BP\>100 mmHg
* In treatment with MAO-inhibitor, SSRIs og Ritalin
Interdisciplinary Value-based Cognitive Behavioral Treatment for People with Traumatic Spinal Cord Injury

The goal of this clinical trial is to address the critical need for effective interventions by developing and testing an interdisciplinary values-based cognitive behavioral therapy (V-CBT) program for individuals with spinal cord injury. The main question it aims to answer are:

* What is the treatment effect of the interdisciplinary values-based cognitive behavioral therapy (V-CBT) program on individuals with spinal cord injury?
* What are the temporal relationships between primary and secondary outcome measures in the context of the V-CBT program?

Participants will undergo a replicated multiple baselines single-case experimental design (SCED). Nine participants who meet specific eligibility criteria will be block-randomized to a 1, 2, or 3-week baseline phase, serving as their own controls. The intervention involves an interdisciplinary team delivering a manualized adapted V-CBT program over ten sessions, focusing on psychological and physical rehabilitation. Participants will be required to attend these sessions either in person at Specialized Hospital for Polio and Accident Victims or virtually via secure videoconferencing as part of the treatment protocol. Data collection includes daily online self-reports and comprehensive measurements at pre-treatment, post- treatment, and a three-month follow-up.


Eligibility Criteria:
Inclusion Criteria:

* be 18 years or older
* speak and read Danish
* aquired spinal cord injury
* paraplegia or tetraplegia (either complete or incomplete)
* daily pain
* therapy-ready and motivated for this treatment type
* willing to engage in homework
* willing to respond to daily questionnaires
* able to attend weekly sessions without payment

Exclusion Criteria:

* any red flags during physiotherapeutic examination
* acute or sub-acute stage
* current pressure ulcers
* known and unstable psychiatric disorder
* syringomyelia
* pregnancy
Impact of Neuropathic Post-Zosterian Pain on the Cognition

Pain is defined as a sensorial and emotional phenomenon and lead consequences on the cognition. These consequences could be increased with usual treatment. So the aim of this study is to explore these cognitive consequences.

Pilot prospective study with parallel groups

Eligibility Criteria:
Inclusion Criteria:

* Patient suffering of NPZ pain
* Over 55 years old
* Healthy volunteers
Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients

Study to evaluate the efficacy of intravenous iron supplementation in the prevention of anemia in patients receiving (neo)adjuvant breast cancer regimens.


Eligibility Criteria:
Inclusion Criteria:

1. Women older than 18 years
2. Patient with operated breast cancer with indication for (NEO)adjuvant therapy
3. They must have hemoglobin levels within the normal range (\> 12g/dL), absence of renal and hepatic dysfunction as assessed by serum levels of urea, creatinine, AST, ALT.
4. Lack of folic acid deficiency and vitamin B12
5. Able to provide written informed consent.

Exclusion Criteria:

1. Use of any oral supplement containing iron;
2. Patients who have iron overload as defined by serum ferritin\> 800 microg / L or transferrin saturation\> 40%;
3. Patients who are pregnant or breastfeeding;
4. History of active infection or active bleeding except menstruation;
5. History of HIV or hepatitis B or C - clinically important; -
Oral Health Training Program for Pediatric Residents

The purpose of this study was to compare the effect of the addition of hands on training by a pediatric dentist on the pediatric residents skills, confidence, opinions and practice related to preventive oral health.

Objectives:

To compare the addition of Hands on Training (HOT) to Web Based Training (WBT)on residents' skills, confidence, opinions and practice .

Methods: Pediatric residents participated in WBT on preventive oral health. Then the WBT subjects were randomly assigned to receive HOT by a dentist, or WBT alone. All subjects were assessed on skills in the performance of an oral exam, by direct observation. Residents' confidence regarding oral health counseling, and their opinions about the importance of the incorporation of oral health into the well child visit, was measured by surveys utilizing a Likert scale. Residents' change in practice was assessed by a retrospective chart audit.

Eligibility Criteria:
Inclusion Criteria:

Pediatric Residents in the Continuity Care Clinics at Children's Mercy Hospital during the months of January and February 2007

Exclusion Criteria:

1. Residents on leave of absence
2. Residents who have their Continuity Care Clinics off site
3. Residents refusing consent for inclusion of results in study
The Effects of Flaxseed Supplement on Weight and Biochemical Factors in Overweight and Obese Subject

To study the effects of Flaxseed supplement on weight, lipid profile and inflammatory factors in subjects with over weight and obesity, 50 patients will be randomly allocated to receive placebo or 30 grams milled Flaxseed for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. At the first and the end of the intervention, weight, waist and hip circumference, lipid profile and some inflammatory markers will be assessed and compared between groups.


Eligibility Criteria:
Inclusion Criteria:

* Age of 18 to 70 years
* Body Mass Index (BMI) between 25-40

Exclusion Criteria:

* diabetes mellitus
* cardiovascular diseases and cancers
* major systemic diseases
* gastrointestinal problems
* liver and renal failure
* history of allergy or high consumption of nuts, flaxseed, or sesame seeds
* weight loss within the past 6 mo of \>5% of body weight or current adherence to a weight-reduction diet
* pregnancy, lactation
A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)

Women with metastatic breast cancer are usually treated with anthracyclines (ie, doxorubicin or epirubicin) but cardiac toxicity limits their use. The aim of this study is to evaluate the safety and efficacy of Caelyx in combination with cyclophosphamide in women with metastatic breast cancer who have received adjuvant anthracyclines with or without a taxane.


Eligibility Criteria:
Inclusion Criteria:

* Female, aged \>=18 years.
* Subject must have histologic diagnosis of breast carcinoma.
* Subject must have documented measurable metastatic breast cancer by appropriate radiologic imaging.
* Subject must have previous anthracyclin-based adjuvant regimen and disease-free status for at least one year following the completion of adjuvant therapy.
* Subject must have ECOG performance status 0, 1, or 2.
* Subject must have life expectancy \> 6 months
* Subject must have left ventricular ejection fraction \>=55% as determined by MUGA scan.
* Subject must have normal organ function, except if abnormal due to tumor involvement:

  * Adequate bone marrow function (platelets \>=100 X 10\^9/L, hemoglobin \>=90 g/L, Neutrophils \>=1.5 X 10\^9/L)
  * Adequate renal function (serum creatinine \< 2 X the upper limit of normal (ULN)
  * Adequate liver function (bilirubin \< 2 times ULN, AST or ALT \< 2 times ULN in the absence of liver metastasis, AST or ALT \< 5 times ULN in the presence of liver metastasis.
* Women of childbearing potential must be using adequate contraception and have a negative pregnancy test at the time of enrollment.
* Subject must be able to understand and give informed consent.

Exclusion Criteria:

* Age \> 75 years old.
* Subject who is pregnant or breastfeeding or is unwilling to use adequate contraception.
* Subject who has had a previous chemotherapy for metastatic disease.
* Subject who has history of cardiac disease, with New York Heart Association Class II or greater with congestive heart failure.
* Subject who has clinically significant hepatic disease in regard to Hepatitis B, Hepatitis C, cirrhosis, or other liver diseases unrelated to the underlying metastatic breast cancer.
* Subject who has uncontrolled bacterial, viral, or fungal infection.
* Subject who exhibits confusion or disorientation.
* Subject with any condition which would prevent adequate follow-up.
* Subject who has received radiotherapy in the last 4 weeks.
* Subject with any other active primary tumor under treatment, except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
* Subject who has brain metastasis.
* Subject who is not able to give informed consent.
Ureteric Stenting Versus Non-stenting Following Uncomplicated Ureteroscopic Lithotripsy

This study aims to compare three groups of patients who underwent uncomplicated ureteroscopic lithotripsy (URSL) to evaluate whether stents could be eliminated after the procedure


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years or older
* unilateral ureteric stones managed by ureteroscopy

Exclusion Criteria:

* Stone size \< 2 cm
* bilateral ureteral stones
* incomplete stone removal due to impacted stones
* failed ureteroscopic access to the stone
* stone migration to the kidney
* pregnancy
* active urinary tract infection
* solitary kidney
* ureteral stent placed preoperatively
* severe mucosal injury or perforation
* suspected additional ureteral pathology such as ureteral stricture
* urothelial carcinoma or polyp.
Minnesota Medicaid Incentives to Prevent Chronic Disease

The objective of this study is to test whether two different participant financial incentive structures are more effective and cost effective than minimal financial incentives in increasing weight loss among Minnesota Medicaid beneficiaries at high risk of developing diabetes. The incentives are tied to participation and weight loss in the evidence-based group-delivered YMCA diabetes prevention program (Y-DPP). The Investigators will conduct a group randomized trial that includes up to 150 Y-DPP classes of 10-15 participants per class for up to 1500 Medicaid beneficiaries participating in the Y-DPP classes. This approach, if successful, will (a) improve weight loss. diabetes risk, and improve cardiovascular risk among Medicaid beneficiaries at risk for developing diabetes and other chronic conditions, (b) demonstrate that prevention of chronic disease risk factors using patient incentives is cost-effective, and (c) provide a patient incentive model that can be widely used among Medicaid beneficiaries at risk for developing diabetes.


Eligibility Criteria:
Inclusion Criteria:

* currently enrolled in Medical Assistance, PMAP, or MinnesotaCare (collectively referred to as Medicaid)
* 18-75 years of age
* body mass index ≥ 25 kg/m2 (≥ 22 kg/m2 for those of Asian descent)
* have prediabetes or a history of gestational diabetes mellitus (GDM)

Exclusion Criteria:

* diagnosis of diabetes
* pregnant at the time of enrollment
* planning gastric bypass surgery within the next 12 months
* diagnosed with Alzheimer's disease (ICD-9 331.0) or dementia (ICD-9 290.0 - 294.9)
* provider judgment regarding suitability for the study based on substance abuse, uncontrolled mental illness, or other conditions that may affect the participants health or ability to participate in the study.